Ponatinib (Iclusig) — Clinical FAQs

Question 1

What is Ponatinib FDA-approved to treat?

Accepted Answer

Ponatinib is FDA-approved for the following oncology indications: 1. Chronic phase (CP), accelerated phase (AP), or blast phase (BP) CML or Ph+ ALL with T315I mutation — approved 2012, reapproved 2013 after voluntary market withdrawal (PACE trial) 2. CP-CML, AP-CML, BP-CML, or Ph+ ALL for which no other TKI therapy is indicated — approved 2012 (PACE trial) 3. CP-CML with the T315I mutation or ≥2 prior TKIs — dose-optimized regimen approved 2022 (OPTIC trial).

Question 2

How does Ponatinib work (mechanism of action)?

Accepted Answer

Ponatinib is a third-generation, pan-BCR-ABL tyrosine kinase inhibitor specifically engineered with a carbon-carbon triple bond linker to circumvent steric hindrance imposed by the T315I gatekeeper mutation, which confers resistance to all first- and second-generation BCR-ABL TKIs. Ponatinib inhibits BCR-ABL and all clinically relevant single-mutant BCR-ABL resistance mutations including T315I with IC50 values in the low nanomolar range. It also potently inhibits VEGFR1-3, PDGFR-α/β, FGFR1-4, KIT, FLT3, and RET, which contributes to both its antineoplastic activity and its vascular toxicity profile. The broad kinase inhibition profile of ponatinib underlies its arterio-occlusive adverse effects mediated through VEGFR and PDGFR inhibition in endothelial and vascular smooth muscle cells.

Question 3

How is Ponatinib administered?

Accepted Answer

Ponatinib is administered Oral (PO). OPTIC dose-optimized regimen (preferred for CP-CML): 45 mg PO once daily until BCR-ABL IS ≤1%, then reduce to 15 mg once daily.

Question 4

What are the most common side effects of Ponatinib?

Accepted Answer

The most commonly reported side effects of Ponatinib (≥10% incidence) include: Rash/dermatologic toxicity (54%), Abdominal pain (49%), Thrombocytopenia (46%), Headache (43%), Constipation (41%) and others (14 total). Consult your oncologist for complete prescribing information.

Question 5

Does Ponatinib have a black box warning?

Accepted Answer

Yes. Ponatinib carries FDA black box warning(s) regarding: 1. Arterial Occlusive Events: Life-threatening and fatal arterial occlusions (fatal MI, stroke, stenosis of large arterial vessels) occurred in at least 35% of patients. Monitor and interrupt or discontinue for vascular events. 2. Venous Thromboembolic Events: Serious and fatal VTE including DVT, PE, and portal vein thrombosis occurred in 6% of patients. 3. Heart Failure: Fatal and life-threatening heart failure or left ventricular dysfunction occurred in 8% of patients; monitor cardiac function. 4. Hepatotoxicity: Fatal hepatic failure occurred; ALT or AST elevation (grade 3-4) occurred in approximately 8-10% of patients. 5. Myelosuppression: Fatal hemorrhage; grade 3-4 myelosuppression in up to 67% of patients. 6. Pancreatitis: Fatal and serious pancreatitis occurred; monitor lipase/amylase; withhold for asymptomatic lipase elevation >2× ULN.

Question 6

Is Ponatinib safe during pregnancy?

Accepted Answer

Ponatinib pregnancy safety: Pregnancy Category D. Ponatinib causes fetal harm based on mechanism of action and animal reproductive studies. Effective contraception required during treatment and for 3 weeks (women) or 1 week (men) after last dose. Breastfeeding is not recommended.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

ponatinib — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms